Novo Nordisk A/S – Share repurchase programme
23 December 2021 - 1:29AM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark,
22 December 2021
– On 5 November 2021, Novo Nordisk initiated a share repurchase
programme in accordance with Article 5 of Regulation No 596/2014 of
the European Parliament and Council of 16 April 2014 (MAR) and the
Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the
"Safe Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 3 February 2021.
Under the programme initiated 5 November 2021, Novo Nordisk will
repurchase B shares for an amount up to DKK 3.7 billion in the
period from 11 November 2021 to 1 February 2022.
Since the announcement 13 December 2021, the following
transactions have been made:
|
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
|
Accumulated, last announcement |
2,225,544 |
|
1,623,730,049 |
| 13 December
2021 |
95,000 |
757.80 |
71,990,640 |
| 14 December
2021 |
100,000 |
748.45 |
74,845,231 |
| 15 December
2021 |
95,000 |
753.30 |
71,563,230 |
| 16 December
2021 |
95,000 |
764.42 |
72,620,345 |
| 17 December
2021 |
95,000 |
764.85 |
72,661,127 |
| 20 December
2021 |
110,000 |
679.26 |
74,718,145 |
| 21 December
2021 |
94,000 |
686.90 |
64,568,776 |
|
Accumulated under the programme |
2,909,544 |
|
2,126,697,543 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
31,099,276 B shares of DKK 0.20 as treasury shares, corresponding
to 1.3% of the share capital. The total amount of A and B shares in
the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 3 February 2021.
As of 21 December 2021, Novo Nordisk has since 3 February 2021
repurchased a total of 32,345,725 B shares at an average share
price of DKK 569.54 per B share equal to a transaction value of DKK
18,422,223,987.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
| Media: |
|
|
| Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
| Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
| Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
| David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
| Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Feb 2024 to Feb 2025
